The clinical effectiveness and cost-effectiveness of treatments for children with idiopathic steroid-resistant nephrotic syndrome: A systematic review

Health Technology Assessment

Volumn 11, Issue 21, 2007, Pages

  Colquitt, Jill L ^a   Kirby, Jo ^a   Green, Colin ^a   Cooper, Keith ^a   Trompeter, Richard S ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKYLATING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEFLAZACORT; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRIL MALEATE; FISH OIL; IMMUNOSUPPRESSIVE AGENT; LEVAMISOLE; LIPID; LOSARTAN; MEDONE; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OLIVE OIL; ONCOVIVN; PLACEBO; PREDNISOLONE; PREDNISONE; PROTEIN; STEROID; TACROLIMUS; UNCLASSIFIED DRUG; UNI E; UNINDEXED DRUG; VINCRISTINE SULFATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ALOPECIA; AMENORRHEA; ANEMIA; ANOREXIA; ARTHRALGIA; ASTHENIA; ASTHMA; AUTONOMIC NEUROPATHY; BACTERIAL ARTHRITIS; BACTERIAL INFECTION; BLOOD DISEASE; BLURRED VISION; BONE MARROW SUPPRESSION; CANDIDIASIS; CARCINOGENESIS; CARDIOMYOPATHY; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COLITIS; CONFUSION; CONTROLLED CLINICAL TRIAL; CONVULSION; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COUGHING; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; CROSSOVER PROCEDURE; DEPRESSION; DIARRHEA; DISORDERS OF ACID BASE BALANCE; DISORDERS OF CARBOHYDRATE METABOLISM; DOSAGE SCHEDULE COMPARISON; DOSE TIME EFFECT RELATION; DROWSINESS; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOXICITY; DRUG WITHDRAWAL; DYSPNEA; ENDOCRINE DISEASE; EPIDERMOLYSIS; ERYTHEMA MULTIFORME; EVIDENCE BASED PRACTICE; EXFOLIATIVE DERMATITIS; FATIGUE; FEASIBILITY STUDY; FLU LIKE SYNDROME; FLUSHING; GAMETOGENESIS; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GLOMERULOSCLEROSIS; HAIR DISEASE; HAIR LOSS; HEALTH CARE COST; HEART ARRHYTHMIA; HEART PALPITATION; HEMATOLOGIC DISEASE; HEMORRHAGIC CYSTITIS; HIRSUTISM; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPERTRICHOSIS; HYPOPHOSPHATEMIA; ILEUS; IMPOTENCE; INFECTION; INSOMNIA; KIDNEY DYSFUNCTION; KIDNEY MALFORMATION; LEUKEMIA; LEUKOPENIA; LIPID BLOOD LEVEL; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FAILURE; LIVER VENOOCCLUSIVE DISEASE; LOW DRUG DOSE; LUNG INFILTRATE; META ANALYSIS; METASTASIS; MONOTHERAPY; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; MYALGIA; MYCOSIS; NAIL COLOR DEFECT; NAUSEA; NEPHROTIC SYNDROME; NEPHROTOXICITY; NERVOUSNESS; NEUROLOGIC DISEASE; NEUROTOXICITY; OBSTRUCTIVE JAUNDICE; OSTEOPENIA; OUTCOMES RESEARCH; PANCREATITIS; PEMPHIGUS; PERIPHERAL NEUROPATHY; PERITONITIS; PLASMAPHERESIS; PNEUMONIA; PROTEINURIA; RAYNAUD PHENOMENON; REMISSION; REVIEW; SEIZURE; SEMEN ABNORMALITY; SEPTICEMIA; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; STEVENS JOHNSON SYNDROME; STOMATITIS; SWEATING; SYNCOPE; SYSTEMATIC REVIEW; TASTE DISORDER; THORAX PAIN; THROMBOCYTOPENIA; TINNITUS; TREATMENT DURATION; TREMOR; UNPLEASANT DREAM; UREA BLOOD LEVEL; URINE LEVEL; UROGENITAL TRACT DISEASE; VASCULITIS; VIRUS INFECTION; VISUAL IMPAIRMENT; VOMITING; ADOLESCENT; CHILD; COST BENEFIT ANALYSIS; DRUG RESISTANCE; GREAT BRITAIN; INFANT; META ANALYSIS (TOPIC); PRESCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DRUG RESISTANCE; GREAT BRITAIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; META-ANALYSIS AS TOPIC; NEPHROTIC SYNDROME; TREATMENT OUTCOME;

EID: 34447581243     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta11210     Document Type: Review

References (70)

1. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet 2003;362:629-39.
2. Koskimies O, Vilska J, Rapola J, Hallman N. Long-term outcome of primary nephrotic syndrome. Arch Dis Child 1982;57:544-8.
3. McKinney PA, Feltbower RG, Brocklebank JT, Fitzpatrick MM. Time trends and ethnic patterns of childhood nephrotic syndrome in Yorkshire, UK. Pediatr Nephrol 2001;16:1040-4.
4. International Study of Kidney Disease in Children. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. J Pediatr 1981;98:561-4.
5. Churg J, Habib R, White RHR. Pathology of the nephrotic syndrome in children. Lancet 1970; i:1299-302.
6. Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 1997;8:769-76.
7. Kim JS, Bellew CA, Silverstein DM, Aviles DH, Boineau FG, Vehaskari VM. High incidence of initial and late steroid resistance in childhood nephrotic syndrome. Kidney Int 2005;68:1275-81.
8. Boute N, Gribouval O, Roselli S, Benessy F, Lee H, Fuchshuber A, et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nature Genet 2006;24:349-54.
9. Ruf RG, Lichtenberger A, Karle SM, Haas JP, Anacleto FE, Schultheiss M, et al. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 2004;15:722-32.
10. White RHR, Glasgow EF, Mills RJ. Clinicopathological study of nephrotic syndrome in childhood. Lancet 1970;i:1353-9.
11. Ahmad H, Tejani A. Predictive value of repeat renal biopsies in children with nephrotic syndrome. Nephron 2000;84:342-6.
12. Southwest Pediatric Nephrology Study Group. Focal segmental glomerulosclerosis in children with idiopathic nephrotic syndrome: a report of the Southwest Pediatric Nephrology Study Group. Kidney Int 1985;27:442-9.
13. Niaudet PA. Steroid-resistant idiopathic nephrotic syndrome in children. In Avner ED, Harmon WE, Niaudet P, editors. Pediatric nephrology. Philadelphia, PA: Lippincott Williams & Wilkins; 2004. pp. 557-73.
14. International Study of Kidney Disease in Children. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. Kidney Int 1978; 13:159-65.
15. Gipson DS, Chin H, Presler DP, Jenette C, Ferris ME, Massengill S, et al. Differential risk of remission and ESRD in childhood FSGS. Pediatr Nephrol 2006; DOI: 10.1007/s00467-005-2123-2.
16. Arneil GC. 164 children with nephrosis. Lancet 1961; ii:1103.
17. Schlesinger ER, Sultz HA, Mosher WE, Feldman JG. The nephrotic syndrome. Its incidence and implications for the community. Am J Dis Child 1968;116:623-32.
18. Bonilla-Felix M, Parra C, Dajani T, Ferris M, Swinford RD, Portman RJ, et al. Changing patterns in the histopathology of idiopathic nephrotic syndrome in children. Kidney Int 1999;55:1885-90.
19. Srivastava T, Simon SD, Alon US. High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood. Pediatr Nephrol 1999; 13:13-18.
20. Ingulli E, Tejani A. Racial differences in the incidence and renal outcome of idiopathic focal segmental glomerulosclerosis in children. Pediatr Nephrol 1991;5:393-7.
21. Sharples PM, Poulton J, White RHR. Steroid responsive nephrotic syndrome is more common in Asians. Arch Dis Child 1985;60:1014-17.
22. Abramowicz M, Barnett HL, Edelmann CM Jr, Greifer I, Kobayashi O, Arneil GC, et al. Controlled trial of azathioprine in children with nephrotic syndrome. A report for the International Study of Kidney Disease in Children. Lancet 1970;i:959-61.
23. Hogg RJ, Portman RJ, Milliner D, Lemley KV, Eddy A, Ingelfinger J. Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics 2000;105:1242-9.
24. Ingulli E, Tejani A. Incidence, treatment, and outcome of recurrent focal segmental glomerulosclerosis posttransplantation in 42 allografts in children - a single-center experience. Transplantation 1991; 51:401-5.
25. Zhao H-Y, Sun R-P, Dong J-H, Zhen J-H. Relations of nuclear factor-kappa B activity in the kidney of children with primary nephrotic syndrome to clinical manifestations, pathological types, and urinary protein excretion. Chin Med J 2005;118:854-6.
26. Kim E-M, Striegel J, Kim Y, Matas AJ, Najarian JS, Mauer SM. Recurrence of steroid-resistant nephrotic syndrome in kidney transplants is associated with increased acute renal failure and acute rejection. Kidney Int 1994;45:1440-5.
27. International Study of Kidney Disease in Children. Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. Kidney International 1981;20:765-71.
28. Niaudet P. Steroid-sensitive idiopathic nephrotic syndrome in children. In Avner ED, Harmon WE, Niaudet P, editors. Pediatric nephrology. Philadelphia, PA: Lippincott Williams & Wilkins; 2004. pp. 543-56.
29. British Association for Paediatric Nephrology. Review of multi-professional paediatric nephrology services in the UK - Towards standards and equity of care. Report of a Working Party of the British Association for Paediatric Nephrology. Bristol: Kubiak Creative; 2003.
30. Mendoza SA, Reznik VM, Griswold WR, Krensky AM, Yorgin PD, Tune BM. Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents. Pediatr Nephrol 1990;4:303-7.
31. Habashy D, Hodson EM, Craig JC. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev 2004;(3).
32. Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children. Pediatric Nephrology 1996;10:590-3.
33. Paediatric Formulary Committee. BNF for children 2005. London: BMJ Publishing Group, Royal Pharmaceutical Society of Great Britain, and RCPCH Publications; 2005.
34. Hari P, Bagga A, Mantan M. Short term efficacy of intravenous dexamethasone and methylprednisolone therapy in steroid resistant nephrotic syndrome. Indian Pediatr 2004;41:993-1000.
35. Durkan A, Hodson E, Willis N, Craig J. Non-corticosteroid treatment for nephrotic syndrome in children [review]. Cochrane Database Syst Rev 2001; (4):CD002290.
36. Joint Formulary Committee. British National Formulary. 52nd ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2006.
37. Burgess E. Management of focal segmental glomerulosclerosis: evidence-based recommendations. Kidney Int Suppl 1999; 55(70):25-32.
38. Chongviriyaphan N, Tapaneya-Olarn C, Suthutvoravut U, Karnchanachumpol S, Chantraruksa V. Effects of tuna fish oil on hyperlipidemia and proteinuria in childhood nephrotic syndrome. J Med Assoc Thail 1999; 82(Suppl 1):122-8.
39. Albon E, Yao GL, Milford D, Adi Y, Bayliss S, Ready A, et al. The clinical and cost effectiveness of immunosuppressive therapy for renal transplantation in children. NICE Report. London: National Institute for Clinical Excellence; 2005.
40. Hodson E. The management of idiopathic nephrotic syndrome in children. Paediatr Drugs 2003;5:335-49.
41. Bagga A, Mudigoudar BD, Hari P, Vasudev V. Enalapril dosage in steroid-resistant nephrotic syndrome. Pediatr Nephrol 2004; 19:45-50.
42. Habashy D, Hodson EM, Craig JC. Interventions for steroid-resistant nephrotic syndrome: a systematic, review. Pediatr Nephrol 2003; 18:906-12.
43. International Study of Kidney Disease in Children. Prospective, controlled trial of cyclophosphamide therapy in children with the nephrotic syndrome. Lancet 1974;ii:423-7.
44. Elhence R, Gulati S, Kher V, Gupta A, Sharma RK. Intravenous pulse cyclophosphamide - a new regime for steroid-resistant minimal change nephrotic syndrome. Pediatr Nephrol 1994;8:1-3.
45. Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1993;43:1377-84.
46. Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol 1996; 7:56-63.
47. Garin EH, Orak JK, Hiott KL, Sutherland SE. Cyclosporine therapy for steroid-resistant nephrotic syndrome. A controlled study. Am J Dis Child 1988; 142:985-8.
48. Adhikari M, Bhimma R, Coovadia HM. Intensive pulse therapies for focal glomerulosclerosis in South African children. Pediatr Nephrol 1997;11:423-8.
49. Gangakhedkar A, Wong W, Pitcher LA. Cerebral thrombosis in childhood nephrosis. J Paediatr Child Health 2005;41:221-4.
50. Gonzalez-Perez JG, Vale L, Stearns SC, Wordsworth S. Hemodialysis for end-stage renal disease: a cost-effectiveness analysis of treatment options. Int J Technol Assess Health Care 2005; 21:32-9.
51. Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, et al. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technol Assess 2005;9(21).
52. Department of Health (UK). NHS reference costs. 2004. URL: http://www.dh.gov.uk/PolicyAndGuidance/OrganisationPolicy/ FinanceAndPlanning/NHSReferenceCosts/fs/en. Accessed January 2006.
53. Netten A, Curtis L. Unit costs of health and social care. University of Kent: PSSRU; 2004.
54. Ruth E-M, Landolt MA, Neuhaus TJ, Kemper MJ. Health-related quality of life and psychosocial adjustment in steroid-sensitive nephrotic syndrome. J Pediatr 2004;145:778-83.
55. Bell CM, Chapman RH, Stone PW, Sandberg EA, Neumann PJ. An off-the-shelf help list: a comprehensive catalog of preference scores from published cost-utility analyses. Med Decis Making 2001;21:288-94.
56. Hlatky MA. Is renal biopsy necessary in adults with nephrotic syndrome. Lancet 1982;ii:1264-8.
57. Kassirer JP. Is renal biopsy necessary for optimal management of the idiopathic nephrotic syndrome? Kidney Int 1983;24:561-75.
58. Levey AS, Lau J, Pauker SG, Kassirer JP. Idiopathic nephrotic syndrome. Puncturing the biopsy myth. Ann Intern Med 1987; 107:697-713.
59. Moxey-Mims MM, Stapleton FB, Feld LG. Applying decision analysis to management of adolescent idiopathic nephrotic syndrome. Pediatr Nephrol 1994;8:660-4.
60. Sarasin FP, Schifferli JA. Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy. Kidney Int 1994;45:578-85.
61. Piccoli A, Pillon L, Passerini P, Ponticelli C. Therapy for idiopathic membranous nephropathy: tailoring the choice by decision analysis. Kidney Int 1994; 45:1193-202.
62. Piccoli A. Elementary clinical decision analysis in evidence-based nephrology J Nephrol 2000;13:419-32.
63. Muirhead N. Management of idiopathic membranous nephropathy: evidence-based recommendations. Kidney Int Suppl 1999; 70:S47-55.
64. Ponticelli C, Zucchelli P, Passerini P, Cesana B. Italian Idiopathic Membranous Nephropathy Treatment Study Group. Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. N Engl J Med 1992; 327:599-603.
65. Ponticelli C, Zucchelli P, Passerini P, Cagnoli L, Cesana B, Pozzi C, et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 1989; 320:8-13.
66. Collaborative Study of the Adult Idiopathic Nephrotic Syndrome. A controlled study of short-term prednisone treatment in adults with membranous nephropathy. N Engl J Med 1979; 301:1301-6.
67. Deeks JJ, Higgins J, Altman DG, editors. Analysing and presenting results. In Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions 4.2.5 [updated May 2005]. URL: http://www.cochrane.org/resources/handbook/hbook.htm. Accessed 20 February 2006.
68. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313:275-83.
69. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004;8(36).
70. NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness. CRD Report 4. 2nd ed. York: University of York; 2001.